AstraZeneca Bolsters Obesity Pipeline with Strategic CSPC Pharma Deal
AstraZeneca has entered a strategic collaboration with China's CSPC Pharmaceutical Group to co-develop and commercialize a portfolio of next-generation therapies for obesity and type 2 diabetes, significantly expanding its weight management pipeline.